- Home
- NFBK vs NPCE Comparison
NFBK vs NPCE Comparison
Compare NFBK & NPCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NFBK | NPCE |
|---|---|---|
| Founded | 1887 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 468.2M | 514.3M |
| IPO Year | 2010 | 2021 |
Fundamental Metrics
Financial Performance| Metric | NFBK | NPCE |
|---|---|---|
| Price | $13.52 | $14.75 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | $13.50 | ★ $18.33 |
| AVG Volume (30 Days) | ★ 438.0K | 143.6K |
| Earning Date | 05-05-2026 | 01-01-0001 |
| Dividend Yield | ★ 3.89% | N/A |
| EPS Growth | N/A | ★ 26.77 |
| EPS | ★ 0.70 | N/A |
| Revenue | $6,430,000.00 | ★ $79,906,000.00 |
| Revenue This Year | $4.95 | $25.95 |
| Revenue Next Year | $6.32 | $0.28 |
| P/E Ratio | $19.10 | ★ N/A |
| Revenue Growth | 17.36 | ★ 22.14 |
| 52 Week Low | $9.40 | $7.56 |
| 52 Week High | $14.05 | $18.97 |
Technical Indicators
Market Signals| Indicator | NFBK | NPCE |
|---|---|---|
| Relative Strength Index (RSI) | 60.13 | 41.93 |
| Support Level | $11.21 | $14.02 |
| Resistance Level | $14.05 | $16.96 |
| Average True Range (ATR) | 0.27 | 0.71 |
| MACD | -0.08 | -0.06 |
| Stochastic Oscillator | 33.54 | 25.05 |
Price Performance
Historical ComparisonAbout NFBK Northfield Bancorp Inc. (Delaware)
Northfield Bancorp Inc is the holding company for Northfield Bank. Its subsidiary provides banking services to individuals and corporate customers in Richmond and Kings Counties in New York, and Hunterdon, Mercer, Union and Middlesex counties in New Jersey. The bank attracts deposits and offers credit and other banking services.
About NPCE Neuropace Inc.
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all of its revenue from the sales of RNS Systems to hospital facilities (typically Level 4 CECs) that implant RNS Systems.